Inner Cosmos

Inner Cosmos has developed a minimally invasive brain-computer interface called the "Digital Pill," which delivers imperceptible micro-stimulations to rebalance brain networks implicated in depression. The company received FDA approval for its first clinical trial for depression and has reported positive interim results from a multi-year human study, including significant mood improvements and remission in some patients. The device avoids direct contact with the brain or blood vessels, reducing risks compared to traditional neurosurgical implants. As of May 2025, interim outcomes from a psychiatric BCI study have been shared publicly.